Research Papers:
The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 3286 views | HTML 5399 views | ?
Abstract
Jeong Hyun Cho1,*, Hyo-Ji Lee1,*, Hyun-Jeong Ko2, Byung-Il Yoon3, Jongseon Choe4, Keun-Cheol Kim1, Tae-Wook Hahn3, Jeong A. Han5, Sun Shim Choi6, Young Mee Jung7, Kee-Ho Lee8, Yun-Sil Lee9, Yu-Jin Jung1
1Department of Biological Sciences, Kangwon National University, Chuncheon, Republic of Korea
2College of Pharmacy, Kangwon National University, Chuncheon, Republic of Korea
3Department of Veterinary Medicine, Kangwon National University, Chuncheon, Republic of Korea
4Department of Microbiology, School of Medicine, Kangwon National University, Chuncheon, Republic of Korea
5Department of Biochemistry and Molecular Biology, School of Medicine, Kangwon National University, Chuncheon, Republic of Korea
6Department of Medical Biotechnology, College of Biomedical Science, Kangwon National University, Chuncheon, Republic of Korea
7Department of Chemistry, Kangwon National University, Chuncheon, Republic of Korea
8Division of Radiation Cancer Research, Korea Institute of Radiological and Medical Sciences, Nowon-gu, Seoul, Republic of Korea
9Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seodaemun-gu, Seoul, Republic of Korea
*These authors have contributed equally to this work
Correspondence to:
Yu-Jin Jung, email: [email protected]
Keywords: melanoma, TLR7, imiquimod (IMQ), autophagy, radiotherapy
Received: February 17, 2016 Accepted: January 23, 2017 Published: February 15, 2017
ABSTRACT
Toll-like receptor (TLR) ligands are strongly considered immune-adjuvants for cancer immunotherapy and have been shown to exert direct anti-cancer effects. This study was performed to evaluate the synergistic anti-cancer and anti-metastatic effects of the TLR7 agonist imiquimod (IMQ) during radiotherapy for melanoma. The pretreatment of B16F10 or B16F1 cells with IMQ combined with γ-ionizing radiation (IR) led to enhanced cell death via autophagy, as demonstrated by increased expression levels of autophagy-related genes, and an increased number of autophagosomes in both cell lines. The results also confirmed that the autophagy process was accelerated via the reactive oxygen species (ROS)-mediated MAPK and NF-κB signaling pathway in the cells pretreated with IMQ combined with IR. Mice subcutaneously injected with melanoma cells showed a reduced tumor growth rate after treatment with IMQ and IR. Treatment with 3-methyladenine (3-MA), ameliorated the anti-cancer effect of IMQ combined with IR. Additionally, the combination therapy enhanced anti-cancer immunity, as demonstrated by an increased number of CD8+ T cells and decreased numbers of regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSCs) in the tumor lesions. Moreover, the combination therapy decreased the number of metastatic nodules in the lungs of mice that were injected with B16F10 cells via the tail vein. In addition, the combination therapy enhanced systemic anti-cancer immunity by increasing the abundances of T cell populations expressing IFN-γ and TNF-α. Therefore, these findings suggest that IMQ could serve as a radiosensitizer and immune booster during radiotherapy for melanoma patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15326